SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers recent climb to a fresh yearly high and move back above a key round-number level is driving attention, with traders celebrating the breakout and bullish momentum. Others question whether the advance can hold, citing resistance, patent-cliff concerns and the lack of a clear new catalyst ahead of the quarterly report.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Attention centers on expectations for Lillys upcoming quarterly report, with traders looking for continued Mounjaro and Zepbound growth and stronger guidance after a recent run to record highs. Bulls see momentum continuing, while skeptics argue expectations are elevated and debate whether oral GLP-1 competition from Novo and Foundayo could challenge Lillys lead.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras investigational treatment for menopausal hot flashes: traders are weighing its positive Phase 2 results and additional clinical data presented at a menopause conference. The reaction is broadly bullish, reinforced by new analyst coverage, but some say the news may already be priced in and emphasize that further trials are needed to confirm the findings.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens IMDELLTRAIMFINZI combination drew attention after Phase 3 results showed a substantial survival benefit in first-line extensive-stage small-cell lung cancer. Traders see the data as a potential growth driver and a boost to Amgens oncology pipeline, while debating how much it could add to the business.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts upcoming quarterly report is the dominant focus, with traders watching Azure growth and whether AI demand can justify rising data-center spending. Views are split between confidence in cloud and AI momentum and concern that heavy capex, delayed returns, and depreciation could pressure margins.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

A sharp rebound and breakout in Atlassian shares, supported by strong cloud growth and repeated analyst upgrades, has fueled bullish momentum and renewed optimism about software stocks ability to benefit from AI. Traders are divided over whether the move can continue or is overextended ahead of earnings, with some warning of a pullback and persistent concerns about valuation and AI disruption.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxon is drawing attention as crude prices rise amid Middle East supply concerns and traders anticipate a strong refining contribution to its upcoming quarterly report. The community is debating whether refining strength can offset weaker upstream results and how long the margin boost will last.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Traders are focused on Brazils presidential runoff and the possibility of Flvio Bolsonaro winning, with speculation that a change in government could bring more shareholder-friendly policies and lift Petrobras shares. Bullish election positioning is tempered by uncertainty about the result and the risk of a sell-the-news reaction; higher oil prices are also supporting the discussion.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Take-private speculation is dominating the discussion after reports that Papa Johns largest U.S. franchisee joined Irth Capitals bid; traders see the added backing as potentially strengthening the deal, but no completed transaction is confirmed. Many remain frustrated that the board rejected earlier offers as weak sales, lower guidance and the dividend suspension weigh on confidence in the standalone turnaround.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons breakout to record highs is drawing attention, with traders pointing to firm crude prices and supply-risk concerns while positioning ahead of its earnings report. Sentiment is mostly bullish, though some question whether strong energy markets will last and whether the rally has already priced in the results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next

Equity

Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.

Definium Reports Second Phase III Success in Anxiety Disorder Program

DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.

DFTX Stock Climbs As High As 12% On ‘Unprecedented’ Anxiety Data For LSD-Based Drug

The company said that the Panorama trial of DT120, a fast-dissolving tablet form of the psychedelic drug lysergide, or LSD, met its main goal in adults with generalized anxiety disorder.


Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'

Definium Therapeutics announced positive Phase 3 Panorama trial results for DT120 in generalized anxiety disorder patients.read more...

Five Stories Putting Traders on Notice: Insider Buying, FDA Catalysts, Psychedelic Breakthroughs and a U.S. Tungsten Rush

The market is once again rewarding investors willing to look beyond the headline indexes; NeOnc Technologies Holdings (NASDAQ:NTHI), Armata Pharmaceuticals (NYSEAMERICAN:ARMP), Definium Therapeutics (NASDAQ:DFTX), Basel Medical Group (NASDAQ:BMGL), Blue Moon Metals (NASDAQ:BMM) and The Elmet Group (NASDAQ:ELMT).

Futures Slide As Tech Tumbles On Fears Of AI Slowdown, Oil Jumps

Futures Slide As Tech Tumbles On Fears Of AI Slowdown, Oil Jumps

 US futures are sliding, dragged by fears of a possible AI development slowdown as well as higher oil prices (Brent > 108), though bond yields are not reacting yet (10Y yield still under 5%). As of 8:00am ET, S&P futures...

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers

Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million.
Definium Therapeutics (NASDAQ:DFTX)read more...

Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

Definium Therapeutics, Inc. (Nasdaq: DFTX) (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Panorama...

DFTX Stock Jumps Overnight As Investors Brace For Phase 3 Results From LSD-Based Anxiety Drug 

Investors are awaiting topline results from Panorama, its second Phase 3 trial of DT120 in generalized anxiety disorder, set to be unveiled on Monday.

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Companys...

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>Biotech still leads year-to-date, with XBI up 26% and IBB up 20%, ahead of SPY’s 12% gain.</li><li>Vera said its kidney drug Trutakna substantially slowed kidney-function decline in the Phase 3 Origin 3 study.</li><li>Ultragenyx is awaiting a Sept.19 FDA decision on UX111, its gene therapy for Sanfilippo syndrome type A.</li></ul><p>Biotech’s 2026 rally cooled this week even as drug developers delivered major clinical updates. Definium Therapeutics (DFTX), Vera Therapeutics (VERA) and GSK (GSK) led the early news cycle, while Ultragenyx Pharmaceutical (RARE) faces the week’s key remaining FDA decision.&nbsp;</p><p>Big Pharma Beats Biotech Sector</p><p>Large-cap healthcare emerged as the relative winner through Tuesday. The&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> gained 1.4% for the week, while the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> fell 1.4%. The&nbsp;<a href="https://stocktwits.com/symbol/IBB">iShares Biotechnology ETF (IBB)</a> slipped 0.5%, compared with declines of 0.9% for the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> and 1.4% for the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a>.</p><p><img src="https://news.stocktwits-cdn.com/healthcare_07fe290fdc.png" alt="healthcare.png"></p><p>On Tuesday, XBI dropped 2.3% to $154.03, and IBB fell 1.3% to $202. XLV was nearly flat at $167.67, while SPY and QQQ declined 0.5% and 0.7%, respectively. However, the year-to-date picture still favors biotech: XBI has gained 26% and IBB 20%, compared with 15% for QQQ, 12% for SPY, and 9% for XLV.</p><h2 class="st-heading-2"><strong>Key Biotech Developments So Far This Week&nbsp;</strong></h2><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col><col></colgroup><tbody><tr><td>Day</td><td>Ticker</td><td>Development</td><td>Key Details</td></tr><tr><td>Monday</td><td>DFTX</td><td>Phase 3 anxiety win</td><td>A single 100-microgram dose of DT120 reduced anxiety scores by 9.8 points at week 12, versus 4.7 for placebo. Definium plans a pre-NDA meeting in the fourth quarter and a filing in the first half of 2027.</td></tr><tr><td>Monday</td><td>GSK</td><td>First-line Jideytro data</td><td>In 94 evaluable, previously untreated ROS1-positive lung cancer patients, GSK reported a 94% response rate and 90% progression-free survival at 12 months.</td></tr><tr><td>Monday</td><td>GSK</td><td>Small-cell lung cancer results</td><td>Median overall survival reached 18.5 months with Risvutatug Rezetecan, versus 10.3 months with Topotecan in a China-based Phase 3 trial.</td></tr><tr><td>Monday-Tuesday</td><td>IBRX</td><td>WCLC and H.C. Wainwright participation</td><td>ImmunityBio was on the conference circuit as investors tracked the commercial rollout of Anktiva.</td></tr><tr><td>Tuesday</td><td>VERA</td><td>Confirmatory ORIGIN 3 results</td><td>Mean kidney-function decline at week 52 was 0.1 with Trutakna versus 5.7 with placebo. Vera plans a fourth-quarter filing for traditional approval.</td></tr><tr><td>Tuesday</td><td>GSK</td><td>Chimagen oncology deal</td><td>GSK agreed to acquire a trispecific multiple-myeloma drug in a deal worth up to $750 million.</td></tr><tr><td>Tuesday</td><td>SMMT</td><td>Ivonescimab at WCLC</td><td>Summit and Akeso presented findings from the Harmoni-2 and global Harmoni lung-cancer programs.</td></tr><tr><td>Tuesday</td><td>BNTX, BMY</td><td>Pumitamig at WCLC</td><td>The companies presented data involving their PD-L1/VEGF bispecific antibody.</td></tr><tr><td>Tuesday</td><td>LEGN</td><td>New CEO</td><td>Legend appointed former Novartis executive Ingrid Zhang as CEO</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>What This Week’s Clinical Results Mean&nbsp;</strong></h2><p>Definium Therapeutics’ (DFTX) DT120 is a fast-dissolving formulation of Lysergide, the pharmaceutical form of LSD. Panorama marked its second successful Phase 3 anxiety trial and third positive late-stage study overall, including one in major depressive disorder.</p><p>GSK’s (GSK) Jideytro is already approved for previously treated ROS1-positive lung cancer after receiving an early FDA nod in July. Its next U.S. catalyst is a filing for first-line use this year. GSK is also running a global Phase 3 study of Risvutatug Rezetecan, an antibody-drug conjugate that carries a cancer-killing payload directly to targeted cells.</p><p>The WCLC presentations also highlighted rising competition among PD-(L)1/VEGF bispecific antibodies. Summit Therapeutics’ (SMMT) Ivonescimab and BioNTech (BNTX)-Bristol Myers Squibb’s (BMY) Pumitamig combine immune-checkpoint inhibition with blocking the blood supply tumors need to grow.</p><p>Vera Therapeutics’ (VERA) Origin 3 study measured eGFR, a key indicator of kidney function. Trutakna received accelerated approval in July based on reducing protein in the urine. Meanwhile, ImmunityBio’s (IBRX) main commercial focus is Anktiva, an IL-15-based immune activator approved with BCG for certain patients with bladder cancer.&nbsp;</p><h2 class="st-heading-2"><strong>New FDA Approvals Put Drug Launches In Focus&nbsp;</strong></h2><p>Scholar Rock Holding (SRRK) entered the week with its first commercial product after the FDA approved Isembyld for spinal muscular atrophy patients already receiving an SMN2-directed therapy. The drug targets myostatin, a protein that restricts muscle growth, making it the first approved muscle-targeted SMA treatment.</p><p>Telix Pharmaceuticals (TLX) received approval for Pixclara, a radioactive PET imaging agent designed to distinguish recurrent or progressing glioma from treatment-related changes. AstraZeneca (AZN), meanwhile, said the Phase 3 Serena-4 study of Camizestrant with Pfizer’s Ibrance failed to delay disease progression in first-line advanced breast cancer.&nbsp;</p><h2 class="st-heading-2"><strong>The Week’s Remaining Healthcare Catalysts&nbsp;</strong></h2><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>What To Watch</td></tr><tr><td>Wednesday, Sept. 16</td><td>GPCR, CMPS, ARWR, JSPR, IBRX</td><td>Final Morgan Stanley and H.C. Wainwright sessions</td></tr><tr><td>Wednesday, Sept.16</td><td>FDA PDUFA meeting</td><td>Discussion of future drug-review commitments, staffing, sponsor meetings, and manufacturing assessments.</td></tr><tr><td>Thursday, Sept.17</td><td>CMPS at Deutsche Bank Healthcare Summit</td><td>Commentary on COMP360.</td></tr><tr><td>Thursday, Sept.17</td><td>Fierce Pharma Week and Neuropsychiatric Drug Development Summit</td><td>Final sessions covering commercialization, medical affairs, and neuroscience drug development.</td></tr><tr><td>Friday, Sept.18</td><td>GSK</td><td>No Jideytro decision is pending.</td></tr><tr><td>Saturday, Sept.19</td><td>RARE - UX111</td><td>FDA decision on Ultragenyx’s gene therapy for Sanfilippo syndrome type A.</td></tr></tbody></table></figure></div><p>The FDA’s Wednesday meeting concerns the next reauthorization of the Prescription Drug User Fee Act, under which drugmakers pay fees that help fund regulatory reviews.&nbsp;</p><p>Meanwhile, Ultragenyx’s UX111 is an AAV9 gene therapy for Sanfilippo syndrome type A, an inherited disease that causes progressive and irreversible neurological decline. The firm is seeking accelerated approval and said UX111 would become the first approved treatment for the disease. The FDA’s earlier complete response letter raised concerns about manufacturing and facility-inspection matters. Since the deadline falls on Saturday, the decision could be disclosed on Friday or during the weekend.&nbsp;</p><h2 class="st-heading-2"><strong>What Biotech Investors Should Watch Next Week&nbsp;</strong></h2><p>Merck (MRK) said Monday, Sept.21 is the FDA deadline for an application seeking an updated U.S. label for Winrevair. Winrevair is approved for pulmonary arterial hypertension, a progressive disease involving elevated pressure in the arteries between the heart and lungs.&nbsp;</p><p>Additionally, Sellas Life Sciences (SLS) will present three preclinical studies of SLS009, or Tambiciclib, at the AACR Conference on Pancreatic Cancer from Sept.25 through Sept. 28. SLS009 blocks CDK9, a protein involved in activating genes cancer cells use to grow and survive. Separately, Sellas is continuing its Phase 3 Regal study of Galinpepimut-S (GPS) in acute myeloid leukemia (AML). Its final analysis will be triggered after the prespecified 80th death, and Sellas had recorded 78 events as of May.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bitcoin-slides-crypto-stocks-decline-as-trump-backed-clarity-act-fails-to-pass-senate-vote/cZto6VyRB2G">Why Did COIN, HOOD, MSTR, ASST, BMNR Stocks Fall Today?&nbsp;</a></p>

AstraZeneca PLC

Glaxosmithkline plc - ADR

iShares Biotechnology ETF

ImmunityBio Inc

Merck & Co Inc

Ultragenyx Pharmaceutical Inc

SELLAS Life Sciences Group Inc

Vera Therapeutics Inc - Ordinary Shares - Class A

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$35.67
Prev Close	$36.00
Open	$36.01
Dividend Yield	0.00%
50-Day Moving Average	$38.57
Beta	1.62
Avg. Volume	2.35M
PE Ratio	-10.37

52-Week High	$49.70
52-Week Low	$10.46
Market Capitalization	$4.79B
EPS (Annual)	-$2.06
Price to Book	5.22
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

DFTX Fundamentals